Multifunctional pro-inflammatory cytokine CXCL8 is a small peptide of 8–10 kDa in size and it functions as a monomer or dimer. CXCL8 harbors 2 disulfide bonds for its stability. Although production of the CXCL8 protein in a large quantity in both mammalian and bacterial systems has been reported, the processes are complicated and lengthy. Here, we develop a new bacterial expression system for recombinant CXCL8 and simplify the purification system to yield a high amount of protein quickly. The purified CXCL8 protein from our new system develops a crystal structure that is identical to that produced through the mammalian expression system. Thus, we have established a simple and efficient recombinant CXCL8-producing system, which can be easily operated and is suitable to those requiring a large quantity of CXCL8.
Get full access to this article
View all access options for this article.
References
1.
AdamsPD, AfoninePV, BunkocziG, ChenVB, DavisIW, EcholsN, HeaddJJ, HungLW, KapralGJ, Grosse-KunstleveRW, McCoyAJ, MoriartyNW, OeffnerR, ReadRJ, RichardsonDC, RichardsonJS, TerwilligerTC, ZwartPH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr, 66(Pt 2):213–221.
2.
BaldwinET, WeberIT, St CharlesR, XuanJC, AppellaE, YamadaM, MatsushimaK, EdwardsBF, CloreGM, GronenbornAM, et al.1991. Crystal structure of interleukin 8: symbiosis of NMR and crystallography. Proc Natl Acad Sci U S A, 88(2):502–506.
3.
BattyeTG, KontogiannisL, JohnsonO, PowellHR, LeslieAG. 2011. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr, 67(Pt 4):271–281.
4.
BricogneG, BlancE, BrandlM, FlensburgC, KellerP, PaciorekW, RoversiP, SharffA, SmartOS, VonrheinC, WomackTO. 2010. BUSTER version 2.9. Cambridge, United Kingdom: Global Phasing. Ltd.
5.
CarpagnanoGE, PalladinoGP, LacedoniaD, KoutelouA, OrlandoS, Foschino-BarbaroMP. 2011. Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8. BMC Cancer, 11:226.
6.
ChengHT, HuangKC, YuHY, GaoKJ, ZhaoX, LiF, TownJ, GordonJR, ChengJW. 2008. A new protocol for high-yield purification of recombinant human CXCL8((3-72))K11R/G31P expressed in Escherichia coli. Protein Expr Purif, 61(1):65–72.
7.
EmsleyP, CowtanK. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr, 60(Pt 12 Pt 1):2126–2132.
8.
FriedlandJS. 1996. Chemokines in viral disease. Res Virol, 147(2–3):131–138.
9.
FurutaR, YamagishiJ, KotaniH, SakamotoF, FukuiT, MatsuiY, SohmuraY, YamadaM, YoshimuraT, LarsenCG, et al.1989. Production and characterization of recombinant human neutrophil chemotactic factor. J Biochem, 106(3):436–441.
10.
GaoY, SangFF, MengL, WangY, MaWT, ChenK. 2019. Preparation of a novel monoclonal antibody against caprine interleukin-17A and its applications in immunofluorescence and immunohistochemistry assays. BMC Biotechnol, 19(1):47.
11.
GuanY, ZhuQ, HuangD, ZhaoS, Jan LoL, PengJ. 2015. An equation to estimate the difference between theoretically predicted and SDS PAGE-displayed molecular weights for an acidic peptide. Sci Rep, 5:13370.
12.
HebertCA, BakerJB. 1993. Interleukin-8: a review. Cancer Invest, 11(6):743–750.
13.
HolmesWE, LeeJ, KuangWJ, RiceGC, WoodWI. 1991. Structure and functional expression of a human interleukin-8 receptor. Science, 253(5025):1278–1280.
14.
HouD, YanZ, ShiJ, HanW, ZhangY. 2005. Expression and one-step ion-exchange purification of (AAR)IL-8 (human IL-8 receptor antagonist). Protein Expr Purif, 44(2):104–109.
15.
KimY, BigelowL, BorovilosM, DementievaI, DugganE, EschenfeldtW, HatzosC, JoachimiakG, LiH, MaltsevaN, MulliganR, QuarteyP, SatherA, StolsL, VolkartL, WuR, ZhouM, JoachimiakA. 2008. Chapter 3. High-throughput protein purification for X-ray crystallography and NMR. Adv Protein Chem Struct Biol, 75:85–105.
LiH, WangD, XuA, LiS, JinS, WuD. 2009. High level expression and purification of active recombinant human interleukin-8 in Pichia pastoris. Protein Expr Purif, 68(1):60–64.
19.
LiuH, MaoP, XieC, XieW, WangM, JiangH. 2015. Association between interleukin 8–251 T/A and +781 C/T polymorphisms and glioma risk. Diagn Pathol, 10:138.
20.
LiuQ, LiA, TianY, WuJD, LiuY, LiT, ChenY, HanX, WuK. 2016. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev, 31:61–71.
21.
LongF, VaginAA, YoungP, MurshudovGN. 2008. BALBES: a molecular-replacement pipeline. Acta Crystallogr D Biol Crystallogr, 64(Pt 1):125–132.
22.
RussoRC, GarciaCC, TeixeiraMM, AmaralFA. 2014. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol, 10(5):593–619.
23.
SchiefnerA, FreierR, EichingerA, SkerraA. 2015. Crystal structure of the human odorant binding protein, OBPIIa. Proteins, 83(6):1180–1184.
24.
SinghRK, LokeshwarBL. 2011. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res, 71(9):3268–3277.
25.
SkerraA. 1994. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene, 151(1–2):131–135.
26.
WaughDJ, WilsonC. 2008. The interleukin-8 pathway in cancer. Clin Cancer Res, 14(21):6735–6741.
27.
WieseD, SchmitzK. 2011. Expression of recombinant human interleukin-8 and its purification using a single buffer system. J Immunol Methods, 364(1–2):77–82.
28.
XieK. 2001. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev, 12(4):375–391.
